Woojin Kang
Papers
1
Total Citations
4
H-Index
1
About
Woojin Kang is a clinical neuroscientist whose research focuses on the pathophysiology and treatment of movement disorders, particularly Parkinson’s disease and levodopa-induced dyskinesia (LID). His major contribution lies in systematically reviewing and synthesizing data from recent and ongoing clinical trials to identify promising therapeutic avenues for LID, a debilitating complication of long-term Parkinson’s treatment. In his most-cited work (2025, 4 citations), Kang critically evaluated pharmacological and non-pharmacological interventions, highlighting that while some agents (e.g., the serotonin agonist zolmitriptan) failed to meet endpoints in Phase II studies, robot-assisted repetitive Transcranial Magnetic Stimulation (rTMS) of the pre-supplementary motor area emerges as a novel, non-invasive approach with potential to alleviate dyskinesia. This work provides a crucial roadmap for future research and clinical practice. Kang’s impact, though early in his career, is marked by his ability to distill complex trial data into actionable insights, bridging the gap between experimental therapies and patient care. His ongoing investigations continue to shape the landscape of movement disorder therapeutics.
Research Focus
Key Achievements
Top Papers
- 1